266 related items for PubMed ID: 14741068
1. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
Murray TJ.
Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
[Abstract] [Full Text] [Related]
2. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
3. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
4. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul 26; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
5. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR, Panitch HS.
Clin Ther; 2007 Sep 26; 29(9):2031-48. PubMed ID: 18035202
[Abstract] [Full Text] [Related]
6. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Etemadifar M, Janghorbani M, Shaygannejad V.
Acta Neurol Scand; 2006 May 26; 113(5):283-7. PubMed ID: 16629762
[Abstract] [Full Text] [Related]
7. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
8. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A, Murray TJ, PROOF Study Investigators.
Curr Med Res Opin; 2008 Apr 10; 24(4):1049-55. PubMed ID: 18315940
[Abstract] [Full Text] [Related]
9. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
[Abstract] [Full Text] [Related]
10. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb 10; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
11. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
Ann Neurol; 1996 Mar 10; 39(3):285-94. PubMed ID: 8602746
[Abstract] [Full Text] [Related]
12. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
Mult Scler; 2009 Aug 10; 15(8):965-76. PubMed ID: 19465443
[Abstract] [Full Text] [Related]
13. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH.
Ann Neurol; 1998 Jan 10; 43(1):79-87. PubMed ID: 9450771
[Abstract] [Full Text] [Related]
14. [Interferon beta-1a (Avonex TM): clinical and MRI impacts].
Vermersch P.
Rev Neurol (Paris); 1999 Jan 10; 155 Suppl 2():S13-9. PubMed ID: 10367320
[Abstract] [Full Text] [Related]
15. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
Sandberg-Wollheim M, Hommes OR, Hughes RA, Paty DW, Abdul-Ahad AK.
Mult Scler; 1995 Jan 10; 1 Suppl 1():S48-50. PubMed ID: 9345399
[Abstract] [Full Text] [Related]
16. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
Mult Scler; 2008 May 10; 14(4):479-84. PubMed ID: 18562504
[Abstract] [Full Text] [Related]
17. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
Neurol Sci; 2005 Dec 10; 26 Suppl 4():S174-8. PubMed ID: 16388353
[Abstract] [Full Text] [Related]
18. Pharmacotherapy of multiple sclerosis: the PROOF trial.
Boster A, Racke MK.
Expert Opin Pharmacother; 2009 Jun 10; 10(8):1235-7. PubMed ID: 19463066
[Abstract] [Full Text] [Related]
19. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
Mult Scler; 2009 Oct 10; 15(10):1195-205. PubMed ID: 19797261
[Abstract] [Full Text] [Related]
20. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
Nafissi S, Azimi A, Amini-Harandi A, Salami S, shahkarami MA, Heshmat R.
Clin Neurol Neurosurg; 2012 Sep 10; 114(7):986-9. PubMed ID: 22429566
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
